PRAEC calls for action on unsafe medicines
The Pharmacovigilance Risk Assessment Expert Committee (PRAEC) — a specialist panel that weighs medicine safety risks — has recommended regulatory action against specified substandard or falsified medical products. The advice also covers enhanced safety monitoring and, in selected cases, suspension of marketing authorisations (the official permission to sell a medicine).
The recommendations were made at the committee’s seventh meeting, held at the Drug Regulatory Authority of Pakistan (DRAP) in Islamabad on 27 October. DRAP is the federal body that oversees medicines and related products in the country.
What the committee reviewed
Members examined domestic medicine safety cases and looked at international regulatory decisions based on pharmacovigilance data — the systematic tracking of how medicines perform once they are in use. The aim was to judge possible risks linked to pharmaceutical products and to support decisions rooted in evidence rather than guesswork.
The meeting also stressed the need to strengthen adverse drug reaction (ADR) reporting. An ADR is a harmful or unwanted effect that may be linked to a medicine. Stronger reporting helps regulators spot problems earlier and act before more patients are exposed.
Why the panel says this matters
PRAEC framed effective pharmacovigilance as a way to catch emerging safety concerns, assess risk, and guide regulatory choices that put patient safety first. Adverse reaction reports, the committee noted, help detect possible medicine-related problems so that timely steps can be taken to protect public health.
The recommendations sit within broader work to tighten medicine safety monitoring and keep regulatory decisions tied to scientific evidence and patient protection. The source material does not name the specific products involved or say when any suspension or other measure would take effect.
Aasan alfaaz mein
Pakistan ke medicine safety panel ne kuch ghalt ya naqli dawaiyon par sakhti ki salah di hai. Kuch cases mein inki sale ki ijazat rokne ki baat bhi ki gayi hai. Yeh faisla Islamabad mein DRAP ke haftwein meeting mein hua. Aam logon ke liye matlab yeh hai ke regulators unsafe dawaiyon ko pehchan kar un par action lene ki taraf badh rahe hain.
